Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...
FierceBiotech4h
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...
Modifi Biosciences Acquired by Merck
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.
FierceBiotech2d
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
pharmaphorum1d
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck & Co/MSD has won approval in ... as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication. Investigator sites are ...
Yahoo Finance22d
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline RAHWAY ...
Reuters27d
Merck's colorectal cancer therapy fails late-stage trial
Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda ... molecules on tumor cells. This activates the body's ...
Pharmabiz8d
Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
Pharmabiz20d
Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma
Merck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage ...
Stockhouse22d
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline ...